Recognizing autoimmune encephalitis as a cause of seizures
Treating cause and not effect
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published April 12, 2019.
Article Versions
- Previous version (April 12, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Jeffrey W. Britton, MD and
- Josep Dalmau, MD
- Jeffrey W. Britton, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Unpaid co-investigator clinical trials: -A Randomized Double Blind Placebo Controlled Study of IVIG in Patients with Voltage Gated Potassium Channel Complex Antibody Associated Autoimmune Epilepsy - Grifols Pharmaceuticals -A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately- controlled seizures- Greenwich Pharmaceuticals - An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes - Greenwich Pharmaceuticals
NONE
NONE
NONE
NONE
Mr. and Mrs. David Hawk charitable gift for epilepsy research
NONE
NONE
NONE
NONE
NONE
NONE
- Josep Dalmau, MD
NONE
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
NONE
NONE
Advance Medical
NONE
NONE
NONE
NONE
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX
NONE
NONE
NONE
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
NONE
NONE
NONE
- From the Division of Epilepsy (J.W.B.) and ICREA and Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic (J.D.), Universitat de Barcelona, Spain; and Department of Neurology(J.D.), University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Britton britton.jeffrey{at}mayo.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.